DE602004022463D1 - Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen - Google Patents

Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen

Info

Publication number
DE602004022463D1
DE602004022463D1 DE602004022463T DE602004022463T DE602004022463D1 DE 602004022463 D1 DE602004022463 D1 DE 602004022463D1 DE 602004022463 T DE602004022463 T DE 602004022463T DE 602004022463 T DE602004022463 T DE 602004022463T DE 602004022463 D1 DE602004022463 D1 DE 602004022463D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
pde5 inhibitor
hypopigmentation disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004022463T
Other languages
English (en)
Inventor
Heidemarie Peuker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SWITCH BIOTECH LLC
Original Assignee
SWITCH BIOTECH LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SWITCH BIOTECH LLC filed Critical SWITCH BIOTECH LLC
Publication of DE602004022463D1 publication Critical patent/DE602004022463D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004022463T 2004-08-19 2004-08-19 Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen Active DE602004022463D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04019695A EP1759700B1 (de) 2004-08-19 2004-08-19 Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen

Publications (1)

Publication Number Publication Date
DE602004022463D1 true DE602004022463D1 (de) 2009-09-17

Family

ID=34926226

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022463T Active DE602004022463D1 (de) 2004-08-19 2004-08-19 Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen

Country Status (6)

Country Link
EP (1) EP1759700B1 (de)
JP (1) JP4904268B2 (de)
AT (1) ATE438403T1 (de)
DE (1) DE602004022463D1 (de)
DK (1) DK1759700T3 (de)
ES (1) ES2330934T3 (de)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834505A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transdermales therapeutisches System zur Anwendung von Sildenafil
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
CA2438272A1 (en) * 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
WO2003074082A1 (en) * 2002-03-06 2003-09-12 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics in cancer treatment
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
EP1597386A1 (de) * 2002-11-13 2005-11-23 Bayer HealthCare AG Diagnoseverfahren und therapeutika für mit humaner phosphodiesterase 2a (pde2a) assoziierte krankheiten
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2004096222A1 (en) * 2003-04-30 2004-11-11 Switch Biotech Ag Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders

Also Published As

Publication number Publication date
EP1759700B1 (de) 2009-08-05
JP4904268B2 (ja) 2012-03-28
DK1759700T3 (da) 2009-10-12
ES2330934T3 (es) 2009-12-17
EP1759700A1 (de) 2007-03-07
ATE438403T1 (de) 2009-08-15
JP2008509944A (ja) 2008-04-03

Similar Documents

Publication Publication Date Title
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
NO20076206L (no) Kombinasjon av PDE4 inhibitor romflumilast og et tetrahydrobioterin-derivativ
ATE527350T1 (de) Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
GB0516156D0 (en) JNK inhibitors
HK1137366A1 (en) Pharmaceutical compositions comprising activin-actriia antagonists and use thereof in preventing or treating multiple myeloma
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2005069865A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
ATE460166T1 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
EP1786428A4 (de) Pde5-hemmer-zusammensetzungen und verfahren zur behandlung von herzerkrankungen
ATE445402T1 (de) Neue verwendung von pde5-hemmern
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ATE551052T1 (de) Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
DE602005010222D1 (de) Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust
DE602004025808D1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
ATE516040T1 (de) Zusammensetzung und verwendung zur vorbeugung oder behandlung von stomatitis
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne

Legal Events

Date Code Title Description
8364 No opposition during term of opposition